Seeking Alpha
20 Nov 2026, 03:59 UTC · 1h ago
Trevi Therapeutics: The P2X3 Collapse Leaves Haduvio Standing Alone In Chronic Cough
Impact · against what's priced in
The news is neutral for TRVI and GSK as the market has already absorbed the failure of camlipixant and the current trial timelines for Haduvio. While the failure of a competitor clears the field, it does not provide a near-term catalyst given that OCEAN data is not expected until 2027/2028.
- GSK−0.10
No priced-in read yet





